Fulgent Genetics (FLGT) Change in Receivables (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Change in Receivables data on file, last reported at -$16.4 million in Q1 2026.

• Quarterly Change in Receivables fell 463.2% year-over-year to -$16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 89.71% YoY) and the FY2025 annual result came in at $23.3 million, up 42.62% from the prior year.
• Change in Receivables eased to -$16.4 million in Q1 2026 per FLGT's latest filing, from $15.4 million in the prior quarter.
• The five-year high for Change in Receivables was $32.9 million in Q1 2022, with the low at -$44.4 million in Q4 2022.
• Average Change in Receivables over 5 years is -$2.8 million, with a median of $1.6 million recorded in 2024.
• Year-over-year, Change in Receivables soared 404.85% in 2025 and plunged 463.2% in 2026.
• Fulgent Genetics' Change in Receivables stood at -$44.4 million in 2022, then jumped by 111.72% to $5.2 million in 2023, then soared by 155.86% to $13.3 million in 2024, then gained by 15.4% to $15.4 million in 2025, then sank by 206.85% to -$16.4 million in 2026.
• Business Quant data shows FLGT's Change in Receivables at -$16.4 million in Q1 2026, $15.4 million in Q4 2025, and -$4.9 million in Q3 2025.